Patents Assigned to UNIVERSITY HEALTH NETWORKS
-
Patent number: 11413094Abstract: Methods and related systems and devices are described for performing various AR medical applications, including a method of guiding augmented reality (AR) intervention. In one aspect, a primary client device: receives model sets, an intervention plan having an intervention field, and session information about a session related to the AR intervention from a server; receives first real-time input data from a first input device; generates metrics by evaluating an execution of the intervention plan by comparing the intervention plan to the first real-time input data; displays real-time graphics, based at least in part on the metrics, spatially over the intervention field; receives real-time status data, from the server, about a replicate client device that joins the session; sends the first real-time input data, the metrics and the evaluation computed from the intervention plan, through the server, to the replicate client device.Type: GrantFiled: May 25, 2020Date of Patent: August 16, 2022Assignee: University Health NetworkInventors: Zigang Jimmy Qiu, Stefan Hofer, Blake Murphy, Tomas J. Saun, Lukasz Brzozowski, Trinette Wright, Xun Lin
-
Publication number: 20220248944Abstract: An endoscopic imaging device is disclosed. The device includes a body portion configured to be held in a user's hand and an endoscope portion configured to direct light onto a target. At least one excitation light source is configured to excite autofluorescence emissions of tissue cells and fluorescence emissions of induced porphyrins in tissue cells of the target. A white light source is configured to illuminate the surgical margin during white light imaging of the target. The device also includes an imaging sensor and a first optical filter configured to filter optical signals emitted by the target responsive to illumination with excitation light and permit passage of autofluorescence emissions of tissue cells and fluorescence emissions of the induced porphyrins in tissue cells to the imaging sensor.Type: ApplicationFiled: January 17, 2020Publication date: August 11, 2022Applicants: University Health Network, SBI ALAPHARMA CANADA INC.Inventors: Ralph S. DACOSTA, Kathryn OTTOLINO-PERRY, Christopher GIBSON, Nayana Thalanki ANANTHA, Simon TREADWELL, Todd DAYNES, Todd MEANEY, Garrett VERMEY, Carl ANNIS
-
Patent number: 11402394Abstract: The disclosure pertains to antibodies and binding fragments thereof that specifically binds all or part of EHAEVVFTA. Also provided are isolated peptides, isolated nucleic acids, immunogens, compositions, immunoassays and kits and method of using said reagents to detect misfolded TTR.Type: GrantFiled: November 23, 2018Date of Patent: August 2, 2022Assignee: University Health NetworkInventors: Avijit Chakrabartty, Rishi Rakhit, Anita Antoinette Bugyei-Twum
-
Patent number: 11395920Abstract: A system and method for identifying a patient-specific neurosurgery target location is provided. The system receives brain imaging data for a patient that includes tracts and networks in the patient brain, accesses a quantitative connectome atlas comprising population-based, disease-specific structural and functional connectivity maps comprising a pattern of tracts and networks associated with an optimal target area (OTA) identified from a population of patients, and defines the patient-specific neurosurgery target location based on a comparison between a pattern of the tracts and networks from the brain imaging data for the patient and the pattern of tracts and networks associated with the OTA identified from the population of patients in the quantitative connectome atlas.Type: GrantFiled: January 22, 2019Date of Patent: July 26, 2022Assignees: General Electric Company, University Health NetworkInventors: Radhika Madhavan, Gavin Elias, Alexandre Boutet, Suresh Joel, Andres M. Lozano
-
Patent number: 11396536Abstract: There is provided herein, the use of mammalian derived HLA class I molecule for in vitro peptide exchange. For example, there is provided a method of producing an HLA class I molecule complexed to a pre-selected peptide comprising: (a) providing a mammalian derived HLA class I molecule complexed to an existing peptide; (b) incubating, in vitro, the HLA class I molecule complexed to the existing peptide with the pre-selected peptide, wherein the pre-selected peptide is at a concentration sufficient to replace the existing peptide to produce the HLA class I molecule complexed to the pre-selected peptide; and the HLA class I molecule comprises ?1, ?2, ?3 and ?2m domains.Type: GrantFiled: April 27, 2017Date of Patent: July 26, 2022Assignee: University Health NetworkInventors: Naoto Hirano, Munehide Nakatsugawa, Muhammed Aashiq Rahman, Kenji Murata
-
Publication number: 20220228120Abstract: Provided herein are enriched populations of ventricular compact cardiomyocytes and enriched populations of mature ventricular or atrial cardiomyocytes, as well as methods of generating the enriched cell populations and methods of using the enriched cell populations in regenerative cardiac cell therapies.Type: ApplicationFiled: May 4, 2020Publication date: July 21, 2022Applicants: UNIVERSITY HEALTH NETWORK, BlueRock Therapeutics LPInventors: Gordon M. Keller, Shunsuke Funakoshi, lan Fernandes, Donghe Yang, Dan Charles Wilkinson, Jr.
-
Patent number: 11385360Abstract: Various embodiments are described herein for sensors that may be used to measure radiation from radiation generating device. The sensors may use a collector plate electrode with first and second collection regions having shapes that are inversely related with one another to provide ion chambers with varying sample volumes along a substantial portion of the first and second collection regions which provides virtual spatial sensitivity during use.Type: GrantFiled: June 3, 2016Date of Patent: July 12, 2022Assignee: University Health NetworkInventors: Mohammad Khairul Islam, Robert K. Heaton, David A. Jaffray, Bernhard Dieter Norrlinger
-
Publication number: 20220211031Abstract: Described are methods of performing perfusion on a heart having a left atrium, a right atrium, a pulmonary artery. The methods are performed on a device configured for selectively performing perfusion in at least a Langendorff mode and a right-sided working mode. The methods include performing profusion on a heart in a right-side working mode of the device in which an aortic line is open, a left atrial line is closed, and a reservoir return line is closed.Type: ApplicationFiled: March 28, 2022Publication date: July 7, 2022Applicant: University Health NetworkInventors: Mitesh Vallabh BADIWALA, Jean W. ZU, Liming XIN, Vivek RAO, Bryan GELLNER, Roberto Vanin Pinto RIBEIRO
-
Patent number: 11375898Abstract: A system for acquiring data regarding a wound in tissue comprises at least one light source configured to directly illuminate a target surface with a homogeneous field of excitation light. An optical sensor is configured to detect signals responsive to illumination of an illuminated portion of a wound and the area around the wound. A thermal sensor is configured to detect thermal information regarding the illuminated portion of the wound and the area around the wound. A processor receives the detected signals and the detected thermal information and outputs data regarding the illuminated portion of the wound and the area around the wound. The output data may include wound size of the illuminated portion of the wound, bacterial load of the illuminated portion of the wound, or at least one temperature associated with the illuminated portion of the wound and the area around the wound. The data output by the processor may be displayed on a display of the system.Type: GrantFiled: May 22, 2015Date of Patent: July 5, 2022Assignee: UNIVERSITY HEALTH NETWORKInventors: Ralph Sebastian Dacosta, Brian C. Wilson, Kai Zhang
-
Publication number: 20220204511Abstract: The present teachings provide a compound represented by the following structural formula: or a pharmaceutically acceptable salt thereof. Also described are pharmaceutical compositions and methods of use thereof.Type: ApplicationFiled: November 8, 2021Publication date: June 30, 2022Applicant: UNIVERSITY HEALTH NETWORKInventors: Radoslaw Laufer, Grace Ng, Sze-Wan Li, Heinz W. Pauls, Yong Liu, Narendra Kumar B. Patel
-
Publication number: 20220168347Abstract: The present disclosure is directed recombinant T cell receptors capable of binding a gp100 epitope and nucleic acid molecules encoding the same. In some embodiments, the nucleic acid molecules further comprise a second nucleotide sequence, wherein the second nucleotide sequence or the polypeptide encoded by the second nucleotide sequence inhibits the expression of an endogenous TCR. Other aspects of the disclosure are directed to vectors comprising the nucleic acid molecule and cells comprising the recombinant TCR, the nucleic acid molecule, or the vector. Still other aspects of the disclosure are directed to methods of using the same. In some embodiments, the methods comprise treating a cancer in a subject in need thereof.Type: ApplicationFiled: March 3, 2020Publication date: June 2, 2022Applicant: University Health NetworkInventors: Naoto HIRANO, Kenji MURATA, Kayoko SASO
-
Publication number: 20220168345Abstract: The present disclosure is directed recombinant T cell receptors capable of binding an NY-ESO-1 epitope and nucleic acid molecules encoding the same. In some embodiments, the nucleic acid molecules further comprise a second nucleotide sequence, wherein the second nucleotide sequence or the polypeptide encoded by the second nucleotide sequence inhibits the expression of an endogenous TCR. Other aspects of the disclosure are directed to vectors comprising the nucleic acid molecule and cells comprising the recombinant TCR, the nucleic acid molecule, or the vector. Still other aspects of the disclosure are directed to methods of using the same. In some embodiments, the methods comprise treating a cancer in a subject in need thereof.Type: ApplicationFiled: March 3, 2020Publication date: June 2, 2022Applicant: University Health NetworkInventors: Naoto HIRANO, Kenji MURATA, Kayoko SASO
-
Publication number: 20220168346Abstract: The present disclosure is directed recombinant T cell receptors capable of binding a gp100 epitope and nucleic acid molecules encoding the same. In some embodiments, the nucleic acid molecules further comprise a second nucleotide sequence, wherein the second nucleotide sequence or the polypeptide encoded by the second nucleotide sequence inhibits the expression of an endogenous TCR. Other aspects of the disclosure are directed to vectors comprising the nucleic acid molecule and cells comprising the recombinant TCR, the nucleic acid molecule, or the vector. Still other aspects of the disclosure are directed to methods of using the same. In some embodiments, the methods comprise treating a cancer in a subject in need thereof.Type: ApplicationFiled: March 3, 2020Publication date: June 2, 2022Applicant: University Health NetworkInventors: Naoto HIRANO, Kenji MURATA, Kayoko SASO
-
Publication number: 20220169696Abstract: The present disclosure is directed recombinant T cell receptors capable of binding a gp100 epitope and nucleic acid molecules encoding the same. In some embodiments, the nucleic acid molecules further comprise a second nucleotide sequence, wherein the second nucleotide sequence or the polypeptide encoded by the second nucleotide sequence inhibits the expression of an endogenous TCR. Other aspects of the disclosure are directed to vectors comprising the nucleic acid molecule and cells comprising the recombinant TCR, the nucleic acid molecule, or the vector. Still other aspects of the disclosure are directed to methods of using the same. In some embodiments, the methods comprise treating a cancer in a subject in need thereof.Type: ApplicationFiled: March 3, 2020Publication date: June 2, 2022Applicant: University Health NetworkInventors: Naoto HIRANO, Kenji MURATA, Kayoko SASO
-
Publication number: 20220169695Abstract: The present disclosure is directed recombinant T cell receptors capable of binding an NY-ESO-1 epitope and nucleic acid molecules encoding the same. In some embodiments, the nucleic acid molecules further comprise a second nucleotide sequence, wherein the second nucleotide sequence or the polypeptide encoded by the second nucleotide sequence inhibits the expression of an endogenous TCR. Other aspects of the disclosure are directed to vectors comprising the nucleic acid molecule and cells comprising the recombinant TCR, the nucleic acid molecule, or the vector. Still other aspects of the disclosure are directed to methods of using the same. In some embodiments, the methods comprise treating a cancer in a subject in need thereof.Type: ApplicationFiled: March 3, 2020Publication date: June 2, 2022Applicant: University Health NetworkInventors: Naoto HIRANO, Kenji MURATA, Kayoko SASO
-
Publication number: 20220152105Abstract: The present disclosure is directed recombinant T cell receptors capable of binding an gp100 epitope and nucleic acid molecules encoding the same. In some embodiments, the nucleic acid molecules further comprise a second nucleotide sequence, wherein the second nucleotide sequence or the polypeptide encoded by the second nucleotide sequence inhibits the expression of an endogenous TCR. Other aspects of the disclosure are directed to vectors comprising the nucleic acid molecule and cells comprising the recombinant TCR, the nucleic acid molecule, or the vector. Still other aspects of the disclosure are directed to methods of using the same. In some embodiments, the methods comprise treating a cancer in a subject in need thereof.Type: ApplicationFiled: March 3, 2020Publication date: May 19, 2022Applicant: University Health NetworkInventors: Naoto HIRANO, Kenji MURATA, Kayoko SASO
-
Publication number: 20220152104Abstract: The present disclosure is directed recombinant T cell receptors capable of binding an NY-ESO-1 epitope and nucleic acid molecules encoding the same. In some embodiments, the nucleic acid molecules further comprise a second nucleotide sequence, wherein the second nucleotide sequence or the polypeptide encoded by the second nucleotide sequence inhibits the expression of an endogenous TCR. Other aspects of the disclosure are directed to vectors comprising the nucleic acid molecule and cells comprising the recombinant TCR, the nucleic acid molecule, or the vector. Still other aspects of the disclosure are directed to methods of using the same. In some embodiments, the methods comprise treating a cancer in a subject in need thereof.Type: ApplicationFiled: March 3, 2020Publication date: May 19, 2022Applicant: University Health NetworkInventors: Naoto HIRANO, Kenji MURATA, Kayoko SASO
-
Publication number: 20220143024Abstract: Provided herein are methods of using ClpP levels and mutation status as a marker for the selection and treatment of cancer patients who will respond to the administration of imipridones. Also provided are methods of treating patients having Perrault syndrome. Also provided are methods of killing bacterial cells and treating bacterial infections using imipridones.Type: ApplicationFiled: February 21, 2020Publication date: May 12, 2022Applicants: Board of Regents, The University of Texas System, University Health NetworkInventors: Michael ANDREEFF, Jo ISHIZAWA, David SCHIMMER, Sara ZARABI
-
Patent number: D958991Type: GrantFiled: January 26, 2021Date of Patent: July 26, 2022Assignees: SBI ALAPHARMA CANADA, INC., UNIVERSITY HEALTH NETWORKInventors: Ralph S. Dacosta, Kathryn Ottolino-Perry, Christopher Gibson, Nayana Thalanki Anantha, Simon Treadwell, Connor Wright, Kimberlyn Dampitan, Todd Daynes, Todd Meaney
-
Patent number: D959666Type: GrantFiled: January 22, 2021Date of Patent: August 2, 2022Assignees: SBI ALAPHARMA CANADA, INC., UNIVERSITY HEALTH NETWORKInventors: Ralph S. Dacosta, Kathryn Ottolino-Perry, Christopher Gibson, Nayana Thalanki Anantha, Simon Treadwell, Todd Daynes, Todd Meaney